ClinicalTrials.gg
CompletedNCT00465803Updated Jul 24, 2014

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Travoprost 0.004%/timolol 0.5% ophthalmic solution and Travoprost ophthalmic solution, 0.004% in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-24.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
30th of 45
81 · median 135
Started
2007
with 4 others
Phase 3
16 of 46
none open now
Registered
9th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 30th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2007, is one of 16 in phase 3, and was the 9th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-angle glaucoma or ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with open-angle glaucoma or ocular hypertension;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Visual acuity worse than 0.60;
  • Other protocol-defined exclusion criteria may apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Other
    DuoTrav

    One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid

    Drug: Travoprost 0.004%/timolol 0.5% ophthalmic solution

  • Other
    Travatan/Timolol

    One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.

    Drug: Travoprost ophthalmic solution, 0.004% · Drug: Timolol maleate ophthalmic solution, 0.5%

Interventions

  • DrugTravoprost 0.004%/timolol 0.5% ophthalmic solution

    Drug page: Travoprost

    One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid

    Also known as: DuoTrav

  • One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid

    Also known as: TRAVATAN

  • One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid

06

What researchers measure

Primary outcomes

  1. Patient compliance

    Patient compliance will be measured with a dosing aid that records time and date of study drug administration

    Time frame: 12 months

07

Study locations

1 site
  • Seattle
    Seattle, Washington 98104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007 and a primary completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2007
First posted
Apr 25, 2007
Start
Mar 2007
Primary completionActual
Jan 2009
Results delay requested
Jul 22, 2014
Last update
Jul 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00465803
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 25, 2007
Start date
Mar 2007
Primary completion
Jan 2009
Last update
Jul 24, 2014

Study contacts

Theresa Landry
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion